

**University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
June 09, 2026**

Members attending the meeting: Bieniek, Kevin; Chatterjee, Bandana; Chen, Chun-Liang; Dell, Shelbie; Ginsburg, Brett; Gould, Georgianna; Kautz, Tiffany; Mishra, Bibhuti; Paukert, Martin; Prewit, Egle; Salamango, Daniel; Shiao, Yuzuru; Vogel, Kristine; Wiederhold, Nathan; Xiang, Yan; Yeh, Chih-Ko; Bloodworth, Rebecca; Macias, Dorothy (alternate for Cerecero, Jennifer - voting)

Guests Present: Rincon, Erica; Melendez, Griselda; Barlett, Emily; Heye, Abby.

Absent members: Cerecero, Jennifer; Burgin, Tiffani; Chen, Ching-Kang Jason; Gauduin, Marie Claire.

1. Panel Chair Announcement

The meeting was called to order at 11:00 a.m. by the IBC Chair, Dr. Yan Xiang.

2. Confidentiality of Panel Proceedings and Conflict of Interest

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. Approval of minutes from the previous meeting

The Committee approved the minutes as written from the May 12, 2026, IBC meeting.

Approved (17 voted to approve, 0 opposed, 0 abstained)

4. Review of Approved Protocols- The spreadsheet of approved protocols for FY2026 will be sent out for review in August 2026.

5. Old Business – None

6. Educational Items – None

7. Occupational Medicine- As of June 1, 2026, there were seven cases of needlesticks, six cases were by UT staff members, and one case was by a UT student. There were six cases of bloodborne exposures: three involving students and three involving UT staff members. There were three cases of Pertussis exposure by UT staff members. There was one case of chemical exposure by a UT staff member. There were two cases

of injuries involving UT staff members, one was a knife cut to a finger, and the other case was an injury to the forearm, pelvis, and lower back.

- 8. Other** – Discussion on ABSL-2 procedures versus ABSL-2 containment, versus ABSL-2 housing. With respect to the administration of biological agents into animals at BSL-2 procedures, which are incorporated into the cells and are not excreted (via respiration, saliva, feces, or through urination). It was agreed upon that an SOP on Animal housing is necessary.

9. Review of EHS Assistant-

Review any issues with the EH&S Assistant program.

10. Meeting Reminder

The next meeting will be held on July 14, 2026.

Protocols for Review

11. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000021868

Principal Investigator: Sharma, Kumar; Medicine-Renal Diseases

Title: NIRVANA (NICotinamide Riboside in SARS-CoV-2 patients for reNAIprotection).

Review Type: Full Committee Review

Form Type: Renewal

Approved (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with human blood and human urine at BSL-2 containment.

Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

12. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000021889

Principal Investigator: Huang, Hui-Ming (Tim); Molecular Medicine

Title: Interrogation of epigenetic regulations in cancer genomes.

Review Type: Full Committee Review

Form Type: Renewal

Approved (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with replication incompetent Lentivirus, human cell lines, lentiviral vector, vectors (FUGW, pLKO.1 puro-CMV TurboGFP+shRNA) at BSL-2 containment. Work with E. coli (lab

strains) and vecor (pCR4-TOPO) at BSL-1 containment.

In vivo:

Work with human cell lines in mice at ABSL-2 containment.

IACUC# 14055X, #20190047AR, #20190047AR, #20200124AR

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

Cloning and vector construction in bacteria and yeasts. III-E, III-F

Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4

13. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000021870

Principal Investigator: Serwer, Philip; Biochemistry & Structural Biology

Title: Novel Data-based analysis and improvement of the Four Key aspects of Phage therapy, NIH-NIBIB-under review-NIH appl. ID-11485793

Review Type: Full Committee Review

Form Type: Renewal

Approved (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with fixed Human brain tissue at BSL-2 containment. Work with E. coli (lab strains), Bacillus thuringensi, Bacillus subtilis, Pseudomonas spp., Streptococcus mutans, Lysinibacillus, Staphylococcus epidermidis, and Bacteriophages at BSL-1 containment.

In vivo:

Work with bacteriophage at ABSL-1 containment.

IACUC# 20200047AP

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

14. Presentation, Discussion, and Voting on a Renewal Protocol:**Protocol ID:** 0000021873**Principal Investigator:** Olsen, Shaun; Biochemistry & Structural Biology**Title:** N/A**Review Type:** Full Committee Review**Form Type:** Renewal**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with human cell lines (HEK293T) transfected with plasmid p-OPIN, Baculovirus, Insect cell lines (Hi5, Sf9) at BSL-2 containment.

Work with E. coli-BL21, E. coli (lab strains) and Bacterial Artificial Chromosomes, and vectors (pET28, pFastBacHTb, pGEX-6p2, pFastBac1, pFastBac-GST, pFastBacDual) at BSL-1 containment.

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Cloning and vector construction in bacteria and yeasts. III-E, III-F

Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

15. Presentation, Discussion, and Voting on a Renewal Protocol:**Protocol ID:** 0000021879**Principal Investigator:** Sun, Luzhe; Cell Systems and Anatomy**Title:** TGF beta.**Review Type:** Full Committee Review**Form Type:** Renewal**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with replication-deficient Lentivirus, human cell lines, and vectors (pLv-STEAP2, pGIPZ, Lov203, pT3, CMV, pHAGE-PIK3CA-H1047R, AOS-Antisense oligonucleotides) at BSL-2 containment.

Work with E. coli (lab strains), plasmids (pT3-EF1a-MYC, pCMV-SB, pT3-EF1a-Steap2, pT3-EF1a-hMET, pT3-EF1a=N90-bCat, pCMV-Tet(Cre-ERT2, pcDNA3), insect cell line (Sf9), AOS-Antisense oligonucleotides at BSL-1 containment.

Work with knock-out mouse strain (C57Bl/6GPx4, C57Bl/PTEN) and transgenic mice (FvBGFP, FvB-Her2, mTmG, K80Cre, K14-Cre, K5-Cre, GFP, p16-3MR, FeJSteap2, FeJAlbCre, FvBStreap2-LoxP) at ABSL-1 containment.

IACUC # 20150076AR, #20150094AR

In vivo:

Work with plamids (pT3-EF1a-MYC, pCMV-SB, pT3-EF1a-Steap2, pT3-EF1a-hMET, pT3-EF1a=N90-bCat, pCMV-Tet(Cre-ERT2, pcDNA3) in knock-out and transgenic mice at ABSL-1 containment.

IACUC# 20150076AR, #20150094AR

Work with replication-deficient lentivirus, human cell lines, plamids (pT3-EF1a-MYC, pCMV-SB, pT3-EF1a-Steap2, pT3-EF1a-hMET, pT3-EF1a=N90-bCat, pCMV-Tet (Cre-ERT2, pcDNA3) and oligonucleotides in knock-out and transgenic mice at ABSL-2 containment.

IACUC# 20150076AR, #20150094AR

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

Cloning and vector construction in bacteria and yeasts. III-E, III-F


Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F

Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F


Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4

Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

Adjourn: The meeting adjourned at 11:55 A.M.



Dr. Yan Xiang
Institutional Biosafety Committee Chair
University of Texas Health San Antonio



Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam